Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777707 | 1.00 | MTOR (1.00) | MTORPIK3CA | |
| SCHEMBL3778333 | 1.00 | MTOR (1.00) | MTORPIK3CA | |
| SCHEMBL3777703 | 1.00 | MTOR (1.00) | MTORPIK3CA | |
| SCHEMBL3788682 | 0.94 | MTOR (0.89) | MTORPIK3CA | |
| SCHEMBL3782857 | 0.94 | MTOR (0.89) | MTORPIK3CA | |
| SCHEMBL3782998 | 0.94 | MTOR (0.89) | MTORPIK3CA | |
| SCHEMBL7762337 | 0.94 | MTOR (0.89) | MTORPIK3CA | |
| SCHEMBL986926 | 0.89 | MTOR (0.81) | MTORPIK3CA | |
| SCHEMBL7763269 | 0.89 | MTOR (0.80) | MTORPIK3CA | |
| SCHEMBL3782576 | 0.89 | MTOR (0.80) | MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151601-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | MTOR 1/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.